Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 4Breast 1

Conditions

Neoplasms 4Breast Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × RG-1507 monoclonal antibody × Clear all
NCT00400361 2016-11-02

A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

Hoffmann-La Roche

Phase 1 Completed
98 enrolled
Tumor-Agnostic

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
104 enrolled
Tumor-Agnostic

Neoplasms

NCT00882674 2016-11-02

A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer

Hoffmann-La Roche

Phase 1 Completed
8 enrolled
Breast

Breast Neoplasms

NCT00985374 2016-11-02

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

NCT00560144 2016-11-01

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Hoffmann-La Roche

Phase 1 Completed
34 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡